ADC · 혈액암 (AML/ALL) | 바이오모아

ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4

효능 ORR 71.7%임상시험 23상태 RECRUITING

ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3

효능 ORR 33.3%임상시험 12상태 RECRUITING

ADCBHotBiologicAcademic and Community Cancer R…Phase 3

Lenvatinib (Lenvatinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · Solid Tumor

#SolidTumor#ADC#Phase3#인기#항체약물접합체+4

효능 ORR 70.3%임상시험 136상태 RECRUITING

ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5

효능 ORR 69.7%임상시험 106상태 RECRUITING

ADCBHotBiologicK-Group, Beta, Inc., a wholly o…atPhase 3

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 50%임상시험 105상태 RECRUITING

ADCBBiologicGileadPhase 2

SG (Sacituzumab Govitecan-hziy, Sacituzumab Govitecan-hziy (SG))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 34.3%임상시험 94상태 RECRUITING

ADCCBiologicCelgenePhase 2

5-Azacytidine (5-Azacytidine)

Leukemia · Leukemia

#Leukemia#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 75%임상시험 89상태 DISCONTINUED

ADCCBiologicAcademic and Community Cancer R…Phase 2

Cabozantinib (Cabozantinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 59%임상시험 89상태 DISCONTINUED

ADCABiologicJanssen Research & Development,…Phase 3

Osimertinib (Osimertinib)

Carcinoma, Non-Small-Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+4

효능 ORR 76.7%임상시험 88상태 RECRUITING

ADCBBiologicDaiichi SankyoPhase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 64%임상시험 88상태 RECRUITING

ADCBBiologicDaiichi Sankyoderuxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 64%임상시험 88상태 RECRUITING

ADCBBiologicGileadaxisPhase 3

sacituzumab govitecan (Trodelvy)

Breast Cancer; Metastatic Breast Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 44%임상시험 87상태 RECRUITING

ADCSBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 79.7%임상시험 84상태 RECRUITING

ADCCBiologicGroupe d'Etude Therapeutique de…Approved

Mercaptopurine (Mercaptopurine)

Crohn's Disease · Leukemia

#Leukemia#ADC#Approved#인기#항체약물접합체+4

효능 ORR 22%임상시험 79상태 RECRUITING

ADCCBiologicNovartis PharmaceuticalsdeliveryPhase 3

Trametinib (Trametinib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 100%임상시험 79상태 DISCONTINUED

ADCBBiologicActinium PharmaceuticalsreleasePhase 2

Daunorubicin (Daunorubicin)

Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia · Leukemia

#Leukemia#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 95%임상시험 72상태 RECRUITING

ADCBBiologicTheRas, Inc., dPhase 2

mFOLFOX6 (mFOLFOX6)

Non-Small Cell Lung Cancer; NSCLC · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 63.64%임상시험 71상태 RECRUITING

ADCBiologicAlliance for Clinical Trials in…releasePhase 3

Daunorubicin Hydrochloride (Daunorubicin Hydrochloride)

B Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase3#인기#항체약물접합체+4

효능 ORR 95%임상시험 69상태 RECRUITING

ADCBiologicMerck Sharp & Dohme LLCPhase 3

Rescue Medication (Rescue Medication)

Non Small Cell Lung Cancer · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase3#인기#항체약물접합체+3

임상시험 69상태 RECRUITING

ADCBiologicNeurocrine UK LimitedhasPhase 2

Therapeutic Hydrocortisone (Therapeutic Hydrocortisone)

Adult Burkitt Lymphoma; B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lympho… · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 6%임상시험 69상태 RECRUITING

1 / 10 페이지

← 이전다음 →